D-Tagatose对心脏病发作风险的影响:随机临床试验的系统审查
Lissé Angarita-Davila1, Héctor Fuentes-Barría2,3, Diana Rojas-Gómez4
1Escuela de Nutrición y Dietética, Facultad de Medicina, Universidad Andres Bello, Concepción 3349001, Chile.
Nutrients
|January 25, 2025
概括
通过降低有害细菌和改善唾液pH值,d-tagatose显示出降低牙风险的希望. 需要进一步的研究来证实口腔护理应用的这些好处.
科学领域:
- 口腔微生物学和牙科
- 碳水化合物的生物化学
- 临床试验分析临床试验分析
背景情况:
- 牙损是一种广泛的疾病,由口腔生物膜失生症引起.
- 突变性链球菌 (Streptococcus mutans) 是导致牙的关键病原体.
研究的目的:
- 为了评估D-塔加在减轻空风险方面的有效性.
- 分析现有的D-塔加和牙的随机临床试验 (RCT).
主要方法:
- 在多个数据库中对到2024年的RCT进行系统文献审查.
- 搜索查询:"塔加托斯或D-塔加托斯以及牙损".
- 纳入标准:评估D-塔加对殖民地形成单位 (CFU) 和唾液pH的影响的研究.
主要成果:
- 三项研究符合标准,显示CFU显著降低和改善唾液pH与D-塔加.
- 与非热量甜味剂或安慰剂相比,D-塔加显示出更好的结果 (p < 0.01).
- 证据质量异质,并指出一些方法上的局限性.
结论:
- D-塔加对降低空白致风险具有潜在的益处.
- 限制包括小样本大小和方法的变化.
- 需要进一步的严格研究来验证D-塔加用于口腔护理配方.
相关概念视频
Carbohydrate Digestion
113.6K
Carbohydrate digestion and metabolism break down simple and complex carbohydrates from food into saccharides (i.e., sugars) for the body to use as energy. Carbohydrate digestion starts in the mouth during mastication, or chewing. The masticated carbohydrates remain intact in the stomach. Digestion resumes in the duodenum of the small intestine, where pancreatic alpha-amylase and brush border enzymes of the microvilli convert complex carbohydrates to monosaccharides. Finally, the monosaccharides...
113.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
148
Hazard Ratio
79
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
79


